Each lot of this antibody is quality control tested by Western blotting. Western blotting, suggested working dilution(s): Use 10 μl per 5 ml antibody dilution buffer for each mini-gel. It is recommended that the reagent be titrated for optimal performance for each application.
MCF-7 cell extract was resolved by electrophoresis, transferred to nitrocellulose,and probed with rabbit
anti-eIF-4E antibody. Proteins were visualized using a donkey anti-rabbit secondary conjugated to HRP and a chemiluminescence detection system.
Description:
eIF-4E (also known as eukaryotic translation initiation factor 4E) is a 25 kD member of the eukaryotic initiation factor 4E family. This ubiquitously expressed cytoplasmic protein recognizes and binds 7-methylguanosine containing mRNA "CAP" during initiation of protein synthesis. eIF-4E facilitates ribosome binding by inducing unwinding of mRNA secondary structures. Activity of this protein is inhibited by binding of 4E-BP and PRH; expression is increased by H2O2 treatment. Activity can also be regulated by integrin α6β4 ligation. Phosphorylation increases binding to mRNA CAPs and formation of eIF4F complex. eIF-4E forms a trimeric complex with eIF-4G, eIF-4A (called eIF-4F). Also associates with 4E-BP and PRH. The Poly6069 antibody has recognizes human eIF-4E and has been shown to be useful for Western blotting.
Other Names:
Eukaryotic translation initiation factor 4E
Structure:
Eukaryotic initiation factor 4E family; 25 kD
Distribution:
Cytoplasm, ubiquitously expressed
Function:
Recognizes and binds 7-methylguanosine containing mRNA "CAP" during initiation of protein synthesis. Facilitates ribosome binding by inducing unwinding of mRNA secondary structures
Regulation:
Inhibited by binding of 4E-BP, PRH. Expression increased by H2O2 treatment. Activity regulated by integrin α6β4 ligation. Phosphorylation increases binding to mRNA CAPs and formation of eIF4F complex
Modification:
Phosphorylation
Interaction:
Forms trimeric complex with eIF-4G, eIF-4A (called eIF-4F). Also associates with 4E-BP, PRH
Antigen References:
1. Rychlik, W., et al., 1987. PNAS 84:945. 2. Topisirovic, I., et al., 2003. EMBO J. 22:689. 3. Shenberger, J., et al., 2002. Am. J. Respir. Cell Mol. Biol. 27:250.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering/). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
